Abstract
The replication licensing factors strictly regulate the DNA replication origin licensing process to guarantee the stability of the genome. Numerous experimental studies have recently demonstrated that the replication licensing factors as oncogenes are essential for the occurrence and development of cancers. Drug resistance, being one of the main characteristics of cancer stem cells, can cause a high recurrence rate and a low survival rate in patients with different cancers. However, the function of the replication licensing factors in cancer stemness remains unclear. The following article highlights the most recent research on DNA replication origin licensing factors in cancer and their function in anti-cancer drug resistance. Moreover, this article proposes a new perspective that replication licensing factors as chemotherapy shield affect anti-cancer drug resistance by promoting the stemness of cancer cells.
| Original language | English |
|---|---|
| Pages (from-to) | 1211-1219 |
| Number of pages | 9 |
| Journal | International Journal of Biological Sciences |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2022 |
Keywords
- cancer stem cell
- drug resistance
- replication initiation factors
- stemness
